Researcher
Steven De Vleeschouwer
- Disciplines:Biomechanics, Morphological sciences, Neurosciences, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Biological and physiological psychology, Cognitive science and intelligent systems, Developmental psychology and ageing
Affiliations
- Research Group Experimental Neurosurgery and Neuroanatomy (Division)
Responsible
From1 Jan 2013 → Today - Research Group Experimental Neurosurgery and Neuroanatomy (Division)
Member
From1 Aug 2001 → Today
Projects
1 - 10 of 22
- Molecular Brain Tumor DetectorFrom1 Feb 2024 → TodayFunding: Other EU initiatives out of framework
- The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomicsFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Immunotherapy for childhood, adolescent, and adult Glioblastoma: towards tumour-immune interactions driven precision medicine using spatially resolved radio-multiomics.From15 Jan 2023 → TodayFunding: BOF - various
- Investigating the role of astrocytes and noradrenaline as critical regulators of neuronal circuit excitability.From1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
- De evidentie rond het coiling-clipping paradigma in de behandeling van cerebrale aneurysmata uitdagen en in kaart brengen door middel van multimodale stratificatie.From8 Dec 2021 → TodayFunding: FWO Strategic Basic Research Grant
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
- Evaluating the Role of Autophagy in the Tumor Vasculature and as Anti-angiogenic Escape MechanismFrom1 Oct 2020 → 30 Sep 2021Funding: BOF - postdoctoral mandates
- Opening the brain blood barrier to treat brain tumoursFrom1 Jan 2020 → 31 Dec 2022Funding: H2020 - European Institute of Innovation and Technology, Horizon Europe - European Institute of Innovation and Technology (EIT)
- Screening of Hyp-PDT induced ICD-sensitive GBM Immunophenotype and Exploration of Synergetic Effect of Sonodynamic Therapy in GBM ImmunotherapyFrom2 Dec 2019 → 2 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Visual prostheses based on high resolution brain stimulationFrom1 Oct 2019 → 30 Sep 2023Funding: BOF - projects
Publications
101 - 110 of 141
- Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response(2014)
Authors: Joost Dejaegher, Stefaan Van Gool, Steven De Vleeschouwer
Pages: 1 - 12 - Defining pseudoprogression in glioblastoma multiforme(2013)
Authors: Agnieszka Wozniak, Joannes Menten, Steven De Vleeschouwer, Frank Van Calenbergh, Raf Sciot, Stefaan Van Gool, Oliver Bechter, Philippe Demaerel, Guy Wilms, Paul Clement
Pages: 1335 - 1341 - Altered galectin-1 serum levels in patients diagnosed with high-grade glioma(2013)
Authors: Tina Verschuere, Matthias Van Woensel, Steffen Fieuws, Stefaan Van Gool, Steven De Vleeschouwer
Pages: 9 - 17 - Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?(2013)
Authors: Matthias Van Woensel, Stefaan Van Gool, Steven De Vleeschouwer
Pages: 1020 - 1048 - Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity(2013)
Authors: Tina Verschuere, Jaan Toelen, Wim Maes, Thomas Tousseyn, Holger Gerhardt, Stefaan Van Gool, Steven De Vleeschouwer
Pages: 873 - 884 - Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination(2012)
Authors: Steven De Vleeschouwer, Frank Van Calenbergh, Raf Sciot, Guy Wilms, Johan van Loon, Jan Goffin, Stefaan Van Gool
Pages: 2105 - 2112 - Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial(2012)
Authors: Stefaan Van Gool, Tina Verschuere, Wim Maes, Steffen Fieuws, Raf Sciot, Guy Wilms, Philippe Demaerel, Jan Goffin, Frank Van Calenbergh, Joannes Menten, et al.
Pages: 2033 - 2044 - Galectin-1 in melanoma biology and related neo-angiogenesis processes(2012)
Authors: Jaan Toelen, Tina Verschuere, Zeger Debyser, Steven De Vleeschouwer, Stefaan Van Gool
Pages: 2245 - 2254 - Ependymomas of the filum terminale:The role of surgery and radiotherapy(2012)
Authors: Frank Van Calenbergh, Joannes Menten, Johan van Loon, Steven De Vleeschouwer, Christiaan Plets, Raf Sciot, Jan Goffin
Pages: 76 - 76 - Gliomas: Diffusion Kurtosis MR Imaging in Grading(2012)
Authors: Ronald Peeters, Uwe Himmelreich, Frederik De Keyzer, Stefaan Van Gool, Frank Van Calenbergh, Steven De Vleeschouwer, Wim Van Hecke, Stefan Sunaert
Pages: 492 - 501
Patents
1 - 3 of 3
- Treatment of central nervous tumours (Inventor)
- Treatment of central nervous tumours (Inventor)
- Treatment of central nervous tumours (Inventor)